FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013150216> ?p ?o ?g. }

• W3013150216 endingPage "687" @default.
• W3013150216 startingPage "674" @default.
• W3013150216 abstract "Amplification of and oncogenic mutations in ERBB2, the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather than its overexpression, are key mechanisms underlying endocytosis and consequent efficacy of the anti-HER2 antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) in lung cancer cell lines and patient-derived xenograft models. These data translated into a 51% response rate in a clinical trial of T-DM1 in 49 patients with ERBB2-amplified or -mutant lung cancers. We show that cotreatment with irreversible pan-HER inhibitors enhances receptor ubiquitination and consequent ADC internalization and efficacy. We also demonstrate that ADC switching to T-DXd, which harbors a different cytotoxic payload, achieves durable responses in a patient with lung cancer and corresponding xenograft model developing resistance to T-DM1. Our findings may help guide future clinical trials and expand the field of ADC as cancer therapy. SIGNIFICANCE: T-DM1 is clinically effective in lung cancers with amplification of or mutations in ERBB2. This activity is enhanced by cotreatment with irreversible pan-HER inhibitors, or ADC switching to T-DXd. These results may help address unmet needs of patients with HER2-activated tumors and no approved targeted therapy.See related commentary by Rolfo and Russo, p. 643.This article is highlighted in the In This Issue feature, p. 627." @default.
• W3013150216 created "2020-04-03" @default.
• W3013150216 creator A5000951196 @default.
• W3013150216 creator A5002819777 @default.
• W3013150216 creator A5004111432 @default.
• W3013150216 creator A5004437156 @default.
• W3013150216 creator A5004669792 @default.
• W3013150216 creator A5006697352 @default.
• W3013150216 creator A5007997858 @default.
• W3013150216 creator A5009003205 @default.
• W3013150216 creator A5010938832 @default.
• W3013150216 creator A5011823761 @default.
• W3013150216 creator A5012322249 @default.
• W3013150216 creator A5014837967 @default.
• W3013150216 creator A5015037150 @default.
• W3013150216 creator A5015397173 @default.
• W3013150216 creator A5023667267 @default.
• W3013150216 creator A5024743507 @default.
• W3013150216 creator A5024882209 @default.
• W3013150216 creator A5025520721 @default.
• W3013150216 creator A5025548835 @default.
• W3013150216 creator A5027332245 @default.
• W3013150216 creator A5029733167 @default.
• W3013150216 creator A5030368651 @default.
• W3013150216 creator A5031241242 @default.
• W3013150216 creator A5036572642 @default.
• W3013150216 creator A5036824862 @default.
• W3013150216 creator A5037092952 @default.
• W3013150216 creator A5039791495 @default.
• W3013150216 creator A5041993659 @default.
• W3013150216 creator A5042115782 @default.
• W3013150216 creator A5049174232 @default.
• W3013150216 creator A5049524331 @default.
• W3013150216 creator A5050763965 @default.
• W3013150216 creator A5053263729 @default.
• W3013150216 creator A5053843638 @default.
• W3013150216 creator A5055884560 @default.
• W3013150216 creator A5057744043 @default.
• W3013150216 creator A5057992394 @default.
• W3013150216 creator A5060228803 @default.
• W3013150216 creator A5060859187 @default.
• W3013150216 creator A5061980954 @default.
• W3013150216 creator A5062167352 @default.
• W3013150216 creator A5068193017 @default.
• W3013150216 creator A5068928963 @default.
• W3013150216 creator A5068943250 @default.
• W3013150216 creator A5073773875 @default.
• W3013150216 creator A5074877517 @default.
• W3013150216 creator A5077235697 @default.
• W3013150216 creator A5080530218 @default.
• W3013150216 creator A5085927402 @default.
• W3013150216 date "2020-05-01" @default.
• W3013150216 modified "2023-10-17" @default.
• W3013150216 title "HER2-Mediated Internalization of Cytotoxic Agents in<i>ERBB2</i>Amplified or Mutant Lung Cancers" @default.
• W3013150216 cites W2002079983 @default.
• W3013150216 cites W2008166288 @default.
• W3013150216 cites W2037690883 @default.
• W3013150216 cites W2048454522 @default.
• W3013150216 cites W2079244398 @default.
• W3013150216 cites W2082664617 @default.
• W3013150216 cites W2089288294 @default.
• W3013150216 cites W2107442883 @default.
• W3013150216 cites W2122766813 @default.
• W3013150216 cites W2133208325 @default.
• W3013150216 cites W2155263737 @default.
• W3013150216 cites W2159192794 @default.
• W3013150216 cites W2168443282 @default.
• W3013150216 cites W2180481128 @default.
• W3013150216 cites W2264000214 @default.
• W3013150216 cites W2270025323 @default.
• W3013150216 cites W2314772071 @default.
• W3013150216 cites W2405513305 @default.
• W3013150216 cites W2517720969 @default.
• W3013150216 cites W2603411876 @default.
• W3013150216 cites W2735084022 @default.
• W3013150216 cites W2767597066 @default.
• W3013150216 cites W2785610956 @default.
• W3013150216 cites W2885615830 @default.
• W3013150216 cites W2889957730 @default.
• W3013150216 cites W2895955393 @default.
• W3013150216 cites W2902218997 @default.
• W3013150216 cites W2907907709 @default.
• W3013150216 cites W2913258427 @default.
• W3013150216 cites W2915968104 @default.
• W3013150216 cites W2934726285 @default.
• W3013150216 cites W2935912602 @default.
• W3013150216 cites W2942867242 @default.
• W3013150216 cites W2943729639 @default.
• W3013150216 cites W2953684910 @default.
• W3013150216 cites W2969544875 @default.
• W3013150216 cites W2970331918 @default.
• W3013150216 cites W2975162457 @default.
• W3013150216 cites W2977889895 @default.
• W3013150216 cites W2995808512 @default.
• W3013150216 cites W2996630100 @default.
• W3013150216 cites W3006146275 @default.
• W3013150216 cites W3010469101 @default.
• W3013150216 doi "https://doi.org/10.1158/2159-8290.cd-20-0215" @default.

• next